Additionally, the overexpression of a mutant PLA2G16 construct in osteosarcoma cells appears to have dominant-negative activity over the wild-type enzyme as the endogenous levels of p-Erk are reduced (Figure 6) and the xenograft model also shows reduced tumor growth in cells expressing the mutant PLA2G16 compared to empty vector controls (Figure 8B, 8C). The gene discussed is PLAAT3; the disease is neoplasm.